Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Dieulafoy lesions and PHACE syndrome.

Kieswetter L, Walters TD, Lara-Corrales I, Carcao MD, Ngan B, Pope E.

Pediatr Dermatol. 2019 Jul 30. doi: 10.1111/pde.13922. [Epub ahead of print]

PMID:
31359449
2.

Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.

Swystun LL, Ogiwara K, Rawley O, Brown C, Georgescu I, Hopman W, Labarque V, Male C, Thom K, Blanchette VS, Carcao M, Lillicrap D.

Blood. 2019 Jul 26. pii: blood.2019000190. doi: 10.1182/blood.2019000190. [Epub ahead of print]

PMID:
31350267
3.

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.

Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E.

Res Pract Thromb Haemost. 2019 Jun 11;3(3):542-554. doi: 10.1002/rth2.12220. eCollection 2019 Jul.

4.

Abnormal fibrinolysis recognized by thromboelastography in a case of severe bleeding with normal coagulation and platelet function, leads to detection of a novel SERPINF2 variant causing severe alpha-2-antiplasmin deficiency.

Egan G, Pluthero FG, Bouskill V, Hilliard P, Drury LJ, Carcao MD, Kahr WHA.

Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16077. [Epub ahead of print] No abstract available.

PMID:
31282989
5.

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A.

van den Berg HM, Fischer K, Carcao M, Chambost H, Kenet G, Kurnik K, Königs C, Male C, Santagostino E, Ljung R; PedNet Study Group.

Blood. 2019 Jul 18;134(3):317-320. doi: 10.1182/blood.2019000658. Epub 2019 Jun 11. No abstract available.

PMID:
31186271
6.

Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?

Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.

J Thromb Haemost. 2019 Jul;17(7):1085-1096. doi: 10.1111/jth.14469. Epub 2019 Jun 2.

PMID:
31038793
7.

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G; Future of Immunotolerance Treatment Group.

Haemophilia. 2019 Jul;25(4):676-684. doi: 10.1111/hae.13762. Epub 2019 Apr 29.

PMID:
31033112
8.

Hemophilia in a Changing Treatment Landscape.

Pelland-Marcotte MC, Carcao MD.

Hematol Oncol Clin North Am. 2019 Jun;33(3):409-423. doi: 10.1016/j.hoc.2019.01.007. Epub 2019 Mar 29. Review.

PMID:
31030810
9.

Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload.

Tole S, Amid A, Baker J, Kuo K, Pugi J, Carcao M.

Acta Haematol. 2019;141(4):256-260. doi: 10.1159/000497175. Epub 2019 Apr 9.

PMID:
30965318
10.

Inhibitors: A Need for Eradication?

Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M.

Acta Haematol. 2019;141(3):151-155. doi: 10.1159/000495454. Epub 2019 Feb 15. Review.

11.

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.

Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G.

Haemophilia. 2018 Nov;24(6):911-920. doi: 10.1111/hae.13608. Epub 2018 Sep 24.

PMID:
30248217
12.

The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH.

Mancuso ME, Bidlingmaier C, Mahlangu JN, Carcao M, Tosetto A; subcommittee on factor viii, factor ix and rare coagulation disorders.

J Thromb Haemost. 2018 Oct;16(10):2106-2110. doi: 10.1111/jth.14257. Epub 2018 Sep 5. No abstract available.

PMID:
30182468
13.

Idiopathic pulmonary arterial hypertension - a unrecognized cause of high-shear high-flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children.

Pelland-Marcotte MC, Humpl T, James PD, Rand ML, Bouskill V, Reyes JT, Bowman ML, Carcao MD.

Br J Haematol. 2018 Oct;183(2):267-275. doi: 10.1111/bjh.15530. Epub 2018 Aug 23.

PMID:
30141279
14.

Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.

Duan L, Renzi S, Weidman D, Waespe N, Chami R, Manson D, Cada M, Carcao M.

J Pediatr Hematol Oncol. 2018 Jul 23. doi: 10.1097/MPH.0000000000001268. [Epub ahead of print]

15.

A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia.

Beck CE, Carcao M, Cada M, Porter S, Blanchette VS, Parkin PC.

J Pediatr Hematol Oncol. 2018 Nov;40(8):e537-e543. doi: 10.1097/MPH.0000000000001247.

PMID:
30028824
16.

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.

Carcao M, Lambert T, Leissinger C, Escuriola-Ettingshausen C, Santagostino E, Aledort L; International Prophylaxis Study Group (IPSG).

Haemophilia. 2018 Nov;24(6):845-848. doi: 10.1111/hae.13558. Epub 2018 Jul 10. No abstract available.

PMID:
29989273
17.

NBEAL2 mutations and bleeding in patients with gray platelet syndrome.

Pluthero FG, Di Paola J, Carcao MD, Kahr WHA.

Platelets. 2018 Sep;29(6):632-635. doi: 10.1080/09537104.2018.1478405. Epub 2018 Jun 5. Review.

PMID:
29869935
18.

Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.

Feldman BM, Rivard GE, Babyn P, Wu JKM, Steele M, Poon MC, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS.

Lancet Haematol. 2018 Jun;5(6):e252-e260. doi: 10.1016/S2352-3026(18)30048-6. Epub 2018 May 3.

PMID:
29731369
19.

Results after laparoscopic partial splenectomy for children with hereditary spherocytosis: Are outcomes influenced by genetic mutation?

Pugi J, Carcao M, Drury LJ, Langer JC.

J Pediatr Surg. 2018 May;53(5):973-975. doi: 10.1016/j.jpedsurg.2018.02.027. Epub 2018 Feb 8.

PMID:
29506817
20.

Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A.

Thromb Haemost. 2018 Mar;118(3):451-460. doi: 10.1055/s-0038-1624581. Epub 2018 Feb 15.

21.

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

Carcao M, Shapiro A, Staber JM, Hwang N, Druzgal C, Lieuw K, Belletrutti M, Thornburg CD, Ahuja SP, Morales-Arias J, Dumont J, Miyasato G, Tsao E, Jain N, Pipe SW.

Haemophilia. 2018 Mar;24(2):245-252. doi: 10.1111/hae.13413. Epub 2018 Feb 13.

22.

Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K; RISE consortium.

Haematologica. 2018 Mar;103(3):550-557. doi: 10.3324/haematol.2017.180059. Epub 2018 Jan 5.

23.

A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.

Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S.

Expert Rev Hematol. 2018 Feb;11(2):87-97. doi: 10.1080/17474086.2018.1419862. Epub 2018 Jan 4. Review.

PMID:
29258406
24.

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.

Platokouki H, Fischer K, Gouw SC, Rafowicz A, Carcao M, Kenet G, Liesner R, Kurnik K, Rivard GE, van den Berg HM.

Haemophilia. 2018 Mar;24(2):283-290. doi: 10.1111/hae.13387. Epub 2017 Dec 15.

PMID:
29243367
25.

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.

Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM; European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group.

Thromb Haemost. 2017 Dec;117(12):2274-2282. doi: 10.1160/TH17-01-0059. Epub 2017 Dec 6.

PMID:
29212115
26.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
27.

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.

Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R.

Br J Haematol. 2017 Oct;179(2):298-307. doi: 10.1111/bjh.14844. Epub 2017 Jul 12.

PMID:
28699675
28.

Switching to extended half-life products in Canada - preliminary data.

Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S; Association of Hemophilia Centre Directors of Canada (AHCDC).

Haemophilia. 2017 Jul;23(4):e365-e367. doi: 10.1111/hae.13245. Epub 2017 May 26. No abstract available.

PMID:
28548284
29.

Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions.

Al-Battat S, Rand ML, Bouskill V, Lau W, Blanchette VS, Kahr WHA, Rivard GE, Carcao MD.

Br J Haematol. 2018 May;181(3):410-413. doi: 10.1111/bjh.14623. Epub 2017 May 3. No abstract available.

PMID:
28466602
30.

Comparing the burden of illness of haemophilia between resource-constrained and unconstrained countries: the São Paulo-Toronto Hemophilia Study.

Carneiro JDA, Blanchette V, Ozelo MC, Antunes SV, Villaca PR, Young NL, Castro D, Brandão LR, Carcao M, Abad A, Feldman BM; São Paulo-Toronto Hemophilia Study Group.

Haemophilia. 2017 Sep;23(5):682-688. doi: 10.1111/hae.13230. Epub 2017 Apr 24.

PMID:
28440005
31.

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia.

Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L; Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators.

Haemophilia. 2017 Sep;23(5):e444-e447. doi: 10.1111/hae.13222. Epub 2017 Apr 24. No abstract available.

PMID:
28439934
32.

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia.

Carcao MD, Avila L, Leissinger C, Blanchette VS, Aledort L.

Haemophilia. 2017 Sep;23(5):e447-e450. doi: 10.1111/hae.13238. Epub 2017 Apr 21. No abstract available.

PMID:
28429874
33.

Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.

Carcao M, Kearney S, Santagostino E, Oyesiku JOO, Young NL, Meunier J, Hoxer CS, Zhang C, Blanchette VS.

Haemophilia. 2017 May;23(3):e222-e224. doi: 10.1111/hae.13195. Epub 2017 Mar 30. No abstract available.

PMID:
28371032
34.

Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A.

Labarque V, Perinparajah V, Bouskill V, Stain AM, Wakefield C, Manuel C, Blanchette VS, James PD, Lillicrap D, Carcao MD.

Am J Hematol. 2017 Jun;92(6):E94-E96. doi: 10.1002/ajh.24709. Epub 2017 Apr 6. No abstract available.

35.

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.

Haemophilia. 2017 Jul;23(4):547-555. doi: 10.1111/hae.13191. Epub 2017 Feb 24.

PMID:
28233381
36.

Effect of moderate intensity exercise on haemostatic capacity in adults with haemophilia A and B: pilot study.

Sholzberg M, Floros G, Schneiderman JE, Kahr WH, Rand M, Pluthero F, Hossain T, Mahamad S, Nisenbaum R, Zhang C, O'Neill NE, Teitel J, Carcao M.

Haemophilia. 2017 Mar;23(2):e162-e165. doi: 10.1111/hae.13181. Epub 2017 Jan 22. No abstract available.

PMID:
28111839
37.

Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.

Fischer K, Poonnoose P, Dunn AL, Babyn P, Manco-Johnson MJ, David JA, van der Net J, Feldman B, Berger K, Carcao M, de Kleijn P, Silva M, Hilliard P, Doria A, Srivastava A, Blanchette V; participants of the International Symposium on Outcome Measures in Hemophilic Arthropathy.

Haemophilia. 2017 Jan;23(1):11-24. doi: 10.1111/hae.13088. Epub 2016 Sep 15. Review.

PMID:
27633342
38.

Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.

Carcao M, Fukutake K, Inbal A, Kerlin B, Lassila R, Oldenburg J, Garly ML, Nugent D.

Semin Thromb Hemost. 2017 Feb;43(1):59-68. doi: 10.1055/s-0036-1585076. Epub 2016 Aug 24.

PMID:
27556350
39.

An institutional pilot study to investigate physical activity patterns in boys with haemophilia.

Bouskill V, Hilliard P, Stephens S, Zhang C, Whitney K, Carcao M.

Haemophilia. 2016 Sep;22(5):e383-9. doi: 10.1111/hae.13021. Epub 2016 Aug 16.

PMID:
27530715
40.

Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.

Crivianu-Gaita V, Rivard GE, Carcao M, Teitel J, St-Louis J, Blanchette V, Pullenayegum E, Abad A, Feldman BM.

Haemophilia. 2016 Sep;22(5):e401-5. doi: 10.1111/hae.13058. Epub 2016 Aug 1.

PMID:
27481574
41.

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.

Carcao M, Zak M, Abdul Karim F, Hanabusa H, Kearney S, Lu MY, Persson P, Rangarajan S, Santagostino E.

J Thromb Haemost. 2016 Aug;14(8):1521-9. doi: 10.1111/jth.13360. Epub 2016 Jun 22.

42.

Impact of aerobic exercise on haemostatic indices in paediatric patients with haemophilia.

Kumar R, Bouskill V, Schneiderman JE, Pluthero FG, Kahr WH, Craik A, Clark D, Whitney K, Zhang C, Rand ML, Carcao M.

Thromb Haemost. 2016 Jun 2;115(6):1120-8. doi: 10.1160/TH15-09-0757. Epub 2016 Feb 25.

PMID:
26917411
43.

Factor VIII/factor IX prophylaxis for severe hemophilia.

Carcao M, Srivastava A.

Semin Hematol. 2016 Jan;53(1):3-9. doi: 10.1053/j.seminhematol.2015.10.006. Epub 2015 Oct 26. Review.

PMID:
26805901
44.

Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.

Ljung R, Fischer K, Carcao M, Santagostino E, Manco-Johnson MJ, Mathew P; INPH group.

Thromb Haemost. 2016 May 2;115(5):913-20. doi: 10.1160/TH15-08-0664. Epub 2016 Jan 21. Review.

PMID:
26791493
45.

Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.

Kumar R, Dunn A, Carcao M.

Semin Thromb Hemost. 2016 Feb;42(1):18-29. doi: 10.1055/s-0035-1568877. Epub 2016 Jan 15. Review.

PMID:
26771678
46.

Optimising musculoskeletal care for patients with haemophilia.

Carcao M, Hilliard P, Escobar MA, Solimeno L, Mahlangu J, Santagostino E.

Eur J Haematol. 2015 Dec;95 Suppl 81:11-21. doi: 10.1111/ejh.12581. Review.

PMID:
26679393
47.

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors.

van den Berg HM, Hashemi SM, Fischer K, Petrini P, Ljung R, Rafowicz A, Carcao M, Auerswald G, Kurnik K, Kenet G, Santagostino E; PedNet Study group.

Thromb Haemost. 2016 Apr;115(4):729-37. doi: 10.1160/TH15-08-0692. Epub 2015 Dec 3.

PMID:
26632988
48.

The role of previously untreated patient studies in understanding the development of FVIII inhibitors.

Carcao M, Re W, Ewenstein B.

Haemophilia. 2016 Jan;22(1):22-31. doi: 10.1111/hae.12790. Epub 2015 Aug 27. Review.

PMID:
26315604
49.

Individualizing factor replacement therapy in severe hemophilia.

Carcao MD, Iorio A.

Semin Thromb Hemost. 2015 Nov;41(8):864-71. doi: 10.1055/s-0035-1552563. Epub 2015 Aug 13. Review.

PMID:
26270111
50.

Vincristine for successful treatment of steroid-dependent infantile hemangiomas.

Wasserman JD, Mahant S, Carcao M, Perlman K, Pope E.

Pediatrics. 2015 Jun;135(6):e1501-5. doi: 10.1542/peds.2014-2542. Epub 2015 May 18.

Supplemental Content

Loading ...
Support Center